Copeptin: A new predictor for severe obstructive sleep apnea

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 589-594

  Çinarka, Halit ^a   Kayhan, Servet ^a   Karataş, Mevlüt ^a   Yavuz, Asiye ^a   GÜmüŞ, Aziz ^a   özyurt, Songül ^a   Cumhur Cüre, Medine ^a   Şahin, Ünal ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

Copeptin; Infammation; Obstructive sleep apnea; Predictor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN;

ADULT; APNEA HYPOPNEA INDEX; AROUSAL INDEX; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DESATURATION INDEX; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; POLYSOMNOGRAPHY; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT PARAMETERS; SENSITIVITY AND SPECIFICITY; SLEEP DISORDERED BREATHING;

EID: 84928111758     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S80779     Document Type: Article

References (33)

1. [No authors listed]. Sleep-related breathing disorders in adults: recommendations for syndrome defnition and measurement techniques in clinical research. Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22:667–689.
2. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003;290: 1906–1914.
3. De Luca Canto G, Pacheco-Pereira C, Aydinoz S, Major PW, Flores-Mir C, Gozal D. Biomarkers associated with obstructive sleep apnea: a scoping review. Sleep Med Rev. 2014;23C:28–45.
4. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL Study. Eur Heart J. 2009;30:1187–1194.
5. Khan SQ, Dhillon OS, O’Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115:2103–2110.
6. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37:145–152.
7. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–1067.
8. Potocki M, Breidthardt T, Mueller A, et al. Copeptin and risk stratifca-tion in patients with acute dyspnea. Crit Care. 2010;14:213–221.
9. Lin Q, Fu F, Chen H, Zhu B. Copeptin in the assessment of acute lung injury and cardiogenic pulmonary edema. Respir Med. 2012;106: 1268–1277.
10. Johns M W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540–545.
11. [No authors listed]. EEG arousals: Scoring rules and examples: a preliminary report from the sleep disorders ATLAS Task Force of the American Sleep Disorders Association. Sleep. 1992;15:173–184.
12. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129–1134.
13. Calvin AD, Albuquerque FN, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea, infammation, and the metabolic syndrome. Metab Syndr Relat Disord. 2009;7:271–278.
14. Potocki M, Reichlin T, Thalmann S, et al. Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocar-dial infarction. Heart. 2010;98:558–565.
15. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66:799–808.
16. Zhu XD, Chen JS, Zhou F, Liu QC, Chen G, Zhang JM. Detection of copeptin in peripheral blood of patients with aneurysmal subarachnoid hemorrhage. Crit Care. 2011;15:R288.
17. Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copep-tin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13: 726–733.
18. Cifçi N, Uyar M, Elbek O, Süyür H, Ekinci E. Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome. Sleep Breath. 2010;14:241–244.
19. Oktay B, Akbal E, Firat H, Ardic S, Akdemir R, Kizilgun M. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath. 2008;12:223–228.
20. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–119.
21. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102–2108.
22. Archontogeorgis K, Nena E, Papanas N, Steiropoulos P. Biomarkers to improve diagnosis and monitoring of obstructive sleep apnea syndrome: current status and future perspectives. Pulm Med. 2014;2014:930535.
23. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046–1053.
24. Ryan S, Taylor CT, McNicholas WT. Systemic infammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax. 2009;64:631–636.
25. Lui MM, Lam JC, Mak HK, et al. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest. 2009;135:950–956.
26. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest. 2004;126:1473–1479.
27. Mehra R, Storfer-Isser A, Kirchner HL, et al. Soluble interleukin 6 receptor: a novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med. 2006;166:1725–1731.
28. Ozben S, Guvenc TS, Huseyinoglu N, et al. Low serum copep-tin levels in patients with obstructive sleep apnea. Sleep Breath. 2013;17:1187–1192.
29. Wang Q, Feng X, Zhou C, Li P, Kang J. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome. Ann Clin Biochem. 2013;50:230–235.
30. Cofta S, Wysocka E, Dziegielewska-Gesiak S, et al. Plasma selectins in patients with obstructive sleep apnea. Adv Exp Med Biol. 2013;756: 113–119.
31. Tauman R, Serpero LD, Capdevila OS, et al. Adipokines in children with sleep disordered breathing. Sleep. 2007;30:443–449.
32. Zhang XB, Lin QC, Deng CS, Chen GP, Cai ZM, Chen H. Elevated serum cystatin C in severe OSA younger men without complications. Sleep Breath. 2013;17:235–241.
33. Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circa-dian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin Chem. 2010;56:1190–1191.